Efficacy of docetasel combined with nedaplatin or cisplatin inpatients with advanced non-small cell lung cancer
Abstract：Objective: To determine the efficacy and side effects of the regimens for combined chemothera-py (docetaxel combined with nedaplatin or cisplatin) in patients with advanced non-small cell lung cancer. Meth-ods: A total of 73 patients with advanced non-small cell lung cancer were divided into two groups, and treated with docetaxel + nedaplatin (test, n=37) or docetaxel + cisplatin (control, n=36). Results: The response rate was 32.43% in test group and 36.11% in control group; there was no significant difference between two groups (P> 0.05). The rate of digestive reactions was significantly lower in test group than in control group (P<0.01). The incidence of leukopenia (24.32% vs 25.00%) and nephrotoxicity were not significantly different in two groups. Thrombocytopenia rate was higher in test group (48.65%) that in control group (27.78%, P<0.05). Conclu-sion: The regimen of nedaplatin combined with docetaxel shows a similar efficacy but a lower digestive reactions as compared with that of cisplatin combined with docetaxel.
Keywords：nedaplatincisplatindocetaselnon-small cell lung cancer (NSCLC)efficacy
Publication Date：2010-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)